Rhythm control versus rate control for atrial fibrillation and heart failure

New England Journal of Medicine

Volumn 358, Issue 25, 2008, Pages 2667-2677

  Roy, Denis ^a   Talajic, Mario ^a   Nattel, Stanley ^a   Wyse, D George ^b   Dorian, Paul ^c   Lee, Kerry L ^d   Bourassa, Martial G ^a   Arnold, J Malcolm O ^e   Buxton, Alfred E ^f   Camm, A John ^g   Connolly, Stuart J ^h   Dubuc, Marc ^a   Ducharme, Anique ^a   Guerra, Peter G ^a   Hohnloser, Stefan H ⁱ   Lambert, Jean ^a   Le Heuzey, Jean Yves ^j   O'Hara, Gilles ^k   Pedersen, Ole Dyg ^l   Rouleau, Jean Lucien ^a   Singh, Bramah N ^m   Stevenson, Lynne Warner ⁿ   Stevenson, William G ⁿ   Thibault, Bernard ^a   Waldo, Albert L ^o   more..

^a MONTREAL HEART INSTITUTE   (Canada)

^b LIBIN CARDIOVASCULAR INSTITUTE OF ALBERTA   (Canada)

^c ST MICHAEL'S HOSPITAL   (Canada)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e LONDON HEALTH SCIENCES CENTRE   (Canada)

^f RHODE ISLAND HOSPITAL   (United States)

^g ST GEORGE S HOSPITAL   (United Kingdom)

^h MCMASTER UNIVERSITY   (Canada)

ⁱ GOETHE UNIVERSITY   (Germany)

^j HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^k LAVAL UNIVERSITY   (Canada)

^l BISPEBJERG HOSPITAL   (Denmark)

^m VETERANS AFFAIRS MEDICAL CENTER   (United States)

ⁿ BRIGHAM AND WOMEN S HOSPITAL   (United States)

^o UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE ANTAGONIST; AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGITALIS; DIGOXIN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOFETILIDE; NITRATE; SOTALOL; VERAPAMIL;

ADULT; AGED; ARTICLE; CAUSE OF DEATH; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; SINUS RHYTHM; STROKE; TREATMENT OUTCOME;

EID: 45549089895     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa0708789     Document Type: Article

References (40)

1. Braunwald E. Shattuck Lecture: cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. N Engl J Med 1997;337:1360-9.
2. 2002 Heart and stroke statistical update. Dallas: American Heart Association, 2002.
3. Nohria A, Lewis E, Stevenson LW. Medical management of advanced heart failure. JAMA 2002;287:628-40.
4. Moser DK, Mann DL. Improving outcomes in heart failure: it's not unusual beyond usual care. Circulation 2002;105:2810-2.
5. Maisel WH, Stevenson LW. Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy. Am J Cardiol 2003;91:Suppl:2D-8D.
6. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998;98:946-52.
7. Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG. Prevalence, age distribution, and gender of patients with atrial fibrillation: analysis and implications. Arch Intern Med 1995;155:469-73.
8. Dries DL, Exner DV, Gersh BJ, Domanski MJ, Waclawiw MA, Stevenson LV. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials: Studies of Left Ventricular Dysfunction. J Am Coll Cardiol 1998;32:695-703.
9. Bourassa MG, Gurné O, Bangdiwala SI, et al. Natural history and patterns of current practice in heart failure. J Am Coll Cardiol 1993;22:Suppl A:14A-19A.
10. Carson PE, Johnson GR, Dunkman WB, Fletcher RD, Farrell L, Cohn JN. The influence of atrial fibrillation on prognosis in mild to moderate heart failure: the V-HeFT Studies. Circulation 1993;87:Suppl VI:VI-102-VI-110.
11. Middlekauff HR, Stevenson WG, Stevenson LW. Prognostic significance of atrial fibrillation in advanced heart failure: a study of 390 patients. Circulation 1991;84:40-8.
12. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:1429-35.
13. Doval HC, Nul DR, Grancelli HO, Perrone SV, Bortman GR, Curiel R. Randomised trial of low-dose amiodarone in severe congestive heart failure. Lancet 1994;344:493-8.
14. Deedwania PC, Singh BN, Ellenbogen K, Fisher S, Fletcher R, Singh SN. Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: observations from the Veterans Affairs Congestive Heart Failure Survival Trial of Antiarrhythmic Therapy (CHF-STAT). Circulation 1998;98:2574-9.
15. AF-CHF Trial Investigators. Rationale and design of a study assessing treatment strategies of atrial fibrillation in patients with heart failure: the Atrial Fibrillation and Congestive Heart Failure (AF-CHF) trial. Am Heart J 2002;144:597-607.
16. Lehto M, Snapinn S, Dickstein K, Swedberg K, Nieminen MS. Prognostic risk of atrial fibrillation in acute myocardial infarction complicated by left ventricular dysfunction: the OPTIMAAL experience. Eur Heart J 2005;26:350-6.
17. Wang TJ, Larson MG, Levy D, et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation 2003;107:2920-5.
18. Mathew J, Hunsberger S, Fleg J, McSherry F, Williford W, Yusuf S. Incidence, predictive factors, and prognostic significance of supraventricular tachyarrhythmias in congestive heart failure. Chest 2000;118:914-22.
19. Zareba W, Steinberg JS, McNitt S, Daubert JP, Piotrowicz K, Moss AJ. Implantable cardioverter-defibrillator therapy and risk of congestive heart failure or death in MADIT II patients with atrial fibrillation. Heart Rhythm 2006;3:631-7.
20. Olsson LG, Swedberg K, Ducharme A, et al. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. J Am Coll Cardiol 2006;47:1997-2004.
21. Grönefeld GC, Hohnloser SH. Heart failure complicated by atrial fibrillation: mechanistic, prognostic, and therapeutic implications. J Cardiovasc Pharmacol Ther 2003;8:107-13.
22. Naccarelli GW, Hynes BJ, Wolbrette DL, et al. Atrial fibrillation in heart failure: prognostic significance and management. J Cardiovasc Electrophysiol 2003;14:Suppl:S281-S286.
23. Ehrlich JR, Nattel S, Hohnloser SH. Atrial fibrillation and congestive heart failure: specific considerations at the intersection of two common and important cardiac disease sets. J Cardiovasc Electrophysiol 2002;13:399-405.
24. Hynes BJ, Luck JC, Wolbrette DL, et al. Atrial fibrillation in patients with heart failure. Curr Opin Cardiol 2003;18:32-8.
25. Coplen SE, Antman EM, Berlin JA, Hewitt P, Chalmers TC. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion: a meta-analysis of randomized controlled trials. Circulation 1990;82:1106-16. [Erratum, Circulation 1991;83:714.]
26. Flaker GC, Blackshear JL, McBride R, Kronmal RA, Halperin JL, Hart RG. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. J Am Coll Cardiol 1992;20:527-32.
27. Stevenson WG, Stevenson LW, Middlekauff HR, et al. Improving survival for patients with atrial fibrillation and advanced heart failure. J Am Coll Cardiol 1996;28:1458-63. [Erratum, J Am Coll Cardiol 1997;30:1902.]
28. Hohnloser SH, Kuck K-H, Lilienthal J. Rhythm or rate control in atrial fibrillation - Pharmacologic Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet 2000;356:1789-94.
29. Brignole M, Menozzi C, Gasparini M, et al. An evaluation of the strategy of maintenance of sinus rhythm by antiarrhythmic drug therapy after ablation and pacing therapy in patients with paroxysmal atrial fibrillation. Eur Heart J 2002;23:892-900.
30. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002;347:1825-33.
31. Van Gelder IC, Hagens VE, Bosker HA, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002;347:1834-40.
32. Carlsson J, Miketic S, Windeler J, et al. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol 2003;41:1690-6.
33. Opolski G, Torbicki A, Kosior DA, et al. Rate control vs rhythm control in patients with nonvalvular atrial fibrillation: the results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) study. Chest 2004;126:476-86.
34. Wyse DG. Rhythm versus rate control trials in atrial fibrillation. J Cardiovasc Electrophysiol 2003;14:Suppl:S35-S39.
35. Fuster V, Rydén LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006;114(7):e257-e354. [Erratum, Circulation 2007;116(6):e138.]
36. Zipes DP, Camm AJ, Borggrefe M, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death - executive summary: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death): developed in collaboration with the European Heart Rhythm Association and Heart Rhythm Society. J Am Coll Cardiol 2006;48:1064-108.
37. Hogg K, Swedberg K, McMurray J. Heart failure with preserved left ventricular systolic function: epidemiology, clinical characteristics, and prognosis. J Am Coll Cardiol 2004;43:317-27.
38. Hsu L-F, Jaïs P, Sanders P, et al. Catheter ablation for atrial fibrillation in congestive heart failure. N Engl J Med 2004;351:2373-83.
39. Stulak JM, Dearani JA, Daly RC, Zehr KJ, Sundt TM III, Schaff HV. Left ventricular dysfunction in atrial fibrillation: restoration of sinus rhythm by the Cox-maze procedure significantly improves systolic function and functional status. Ann Thorac Surg 2006;82:494-501.
40. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005;352:225-37. [Erratum, N Engl J Med 2005;352:2146.]